The results of the present study are along the lines of several other reports demonstrating that tumour mRNA expression of RRM1 was correlated with clinical response to gemcitabine/cisplatin in stage IV NSCLC (Rosell et al, 2003, 2004; Ceppi et al, 2006). This evidence concerns the gene RRM1 and neoplasm.